In Phase I, the ACCISS Study commissioned a first-of-its-kind report on the Insulin Market.
This profile identifies insulin manufacturers and countries where their products are registered and/or sold, the inclusion of insulin in national essential medicines lists, insulin product registration data, recent studies on the efficacy and safety of analogue and human insulin, and an estimate of the rate of insulin consumption for people with type 2 diabetes.
Self-monitoring of blood glucose is an essential aspect to diabetes care for people with type 1 diabetes, and for many with type 2 diabetes, particularly those who use insulin. To better understand the barriers to access to monitoring devices, the ACCISS Study, together with FIND, the global alliance for diagnostics, commissioned a report by the Clinton Health Access Initiative (CHAI) that outlined the current issues with access to self-monitoring devices.
List of know insulin providers and distributors, compiled by ACCISS (updated annually)
The production and use of generic medicines has substantially improved access to medicines in low-income and middle-income countries. The authors visited six biosimilar insulin manufacturers to better understand the challenges and opportunities that they face in supplying insulin globally.
This profile uses data from various sources, including the United States Food and Drug Administration’s Orange Book and Health Canada, to determine the patent status of analogue and human insulins, and whether patents are a barrier to accessing insulin
From available trade databases and published literature, this profile maps the global trade of retail insulin and bulk insulin to show importing and exporting countries and their importance in global insulin trade. Countries that import insulin from only one country, making them vulnerable to possible disruptions in supply, are also identified.